Oncology Resource Group (ONCrg) is an accomplished team of competitive intelligence professionals with strong scientific, clinical, and commercial proficiencies. Our analysts cultivate their unmatched expertise through continuous study of solid tumors, hematologic malignancies, and immuno-oncology to deliver unique, year-round competitive intelligence. ONCrg’s medical congress, competitive landscape, and surveillance reports provide unparalleled depth, breadth, and insight in each of our practice areas.
Sarah Lockhead Ph.D.
Disease Area Manager
Sarah received her Ph.D. in Chemical and Systems Biology from Stanford University and years spent in various drug development roles ranging from preclinical oncology portfolio development at Pfizer to drug repurposing at Stanford’s School of Medicine, en- ables her to provide clients with incisive analyses. Through the ONCrg Advisory services, you can contact Sarah directly for personalized answers to non-proprietary questions, targeted analyses, and custom insights in Bladder Cancer.
Nikki Trunnell, Ph.D.
Operations Director, ONCrg
Nikki received her Ph.D. in Cancer Biology from Stanford University School of Medicine and has been supporting bio-pharmaceutical companies with her expertise in epidemiology, market forecasting, and the integration of primary and secondary research. Nikki co-manages ONCrg and serves clients through her thorough knowledge of oncology, strong scientific/clinical acumen, and command of market research and analytical method.
Pricing and More Information:
Call: 650-485-2626
Visit: www.onc-rg.com
Email: michael.reynolds@onc-rg.com
ONCrg Conference™ delivers unrivaled competitive intelligence from major congresses. ONCrg’s syndicated model covers the entire Bladder Cancer landscape, but leaves room to add or drill down on your interests. Highly relevant reports capture key data and include our expert opinions about the implications of new data on your pipeline.
Competitive Landscape Analysis*
ONCrg Pipeline Strategies™ delivers cutting-edge profiles across the entire Bladder Cancer competitive landscape, providing valuable analytics by class and treatment subset for new drugs in Phase I/II development and beyond. Reports are updated quarterly and written in two formats:
- a presentation format for higher level comparative analytics
- a corresponding compendium with additional detailed commentary from ONCrg experts
Monthly Surveillance Reports
ONCrg Sentinel™ provides vigilant monitoring of rapidly evolving scientific, clinical, and commercial activities in Bladder Cancer. ONCrg experts identify and analyze events to deliver incisive commentaries each month that inform subscribers and prepare them to respond wisely to changing market conditions.
Expert Advisory Guidance
ONCrg Advisory™ is an open door to ask non-proprietary questions in Bladder Cancer and your other subscription areas. Our experts utilize extensive resources and experience to provide extra guidance to inform clients’ key decisions.